Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis

被引:0
|
作者
Tjalf Ziemssen
机构
[1] Technical University of Dresden,Neurological University Clinic
[2] Medical Faculty “Carl Gustav Carus”,undefined
来源
Journal of Neurology | 2005年 / 252卷
关键词
multiple sclerosis; neurodegeneration; neuroprotection; inflammation; treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Historically considered to be an autoimmune demyelinating disease, multiple sclerosis is now recognized to be characterized by significant axonal and neuronal pathology. Addressing this neurodegenerative component of the disease is an important treatment objective, since axonal injury is believed to underlie the accumulation of disability and disease progression. The precise relationship between the inflammatory and neurodegenerative components in multiple sclerosis remains poorly elucidated, although neurodegeneration appears to be at least partially independent from neuroinflammation. The mechanisms underlying axonal injury appear complex and are likely to be multifactorial. Specific treatment strategies need to be developed that act within the central nervous system to prevent neurodegeneration and need to be provided from the earliest stages of disease. It is likely that immunomodulatory treatments acting purely in the periphery will provide only indirect and not direct neuroprotection. A promising approach is to enhance neuroprotective autoimmunity inside the brain, believed to be mediated, at least in part, by the release of neurotrophic factors within the nervous system from infiltrating immune cells. Such a beneficial process would be inhibited by a non-selective immunosuppressive strategy. In summary, treatments of multiple sclerosis should take into account the heterogeneous pathophysiology of the disease. The pathogenic process in the central nervous system itself should be the major focus in multiple sclerosis therapy in order to protect against demyelination and axonal loss and to promote remyelination and regeneration directly in the target tissue, independently of peripheral immune status. In conclusion, selective treatment strategies aimed at preventing axonal injury within the central nervous system are required to complement existing, peripherally acting treatments targeting the immune system.
引用
收藏
页码:v38 / v45
相关论文
共 50 条
  • [21] Central nervous system remyelination in culture - A tool for multiple sclerosis research
    Zhang, Hui
    Jarjour, Andrew A.
    Boyd, Amanda
    Williams, Anna
    EXPERIMENTAL NEUROLOGY, 2011, 230 (01) : 138 - 148
  • [22] A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis
    Eckstein, Christopher
    Saidha, Shiv
    Levy, Michael
    JOURNAL OF NEUROLOGY, 2012, 259 (05) : 801 - 816
  • [23] Central Nervous System B-Cell Lymphoma in Multiple Sclerosis
    Lyons, Mark
    Patel, Naresh
    Birch, Barry
    Boucher, Orland
    TURKISH NEUROSURGERY, 2012, 22 (04) : 493 - 495
  • [24] Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System
    Rajda, Cecilia
    Majlath, Zsofia
    Pukoli, Daniel
    Vecsei, Laszlo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (08): : 18270 - 18282
  • [25] A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis
    Christopher Eckstein
    Shiv Saidha
    Michael Levy
    Journal of Neurology, 2012, 259 : 801 - 816
  • [26] Is multiple sclerosis a generalized disease of the central nervous system? An MRI perspective
    Chard, Declan
    Miller, David
    CURRENT OPINION IN NEUROLOGY, 2009, 22 (03) : 214 - 218
  • [27] Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis
    Schrijver, IA
    van Meurs, M
    Melief, MJ
    Ang, CW
    Buljevac, D
    Ravid, R
    Hazenberg, MP
    Laman, JD
    BRAIN, 2001, 124 : 1544 - 1554
  • [28] Cytokines in the Central Nervous System: Targets for Therapeutic Intervention
    Safieh-Garabedian, Bared
    Haddad, John J.
    Saade, Nayef E.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (04) : 271 - 280
  • [29] Microglia as therapeutic targets for central nervous system remyelination
    Mahmood, Ayisha
    Miron, Veronique E.
    CURRENT OPINION IN PHARMACOLOGY, 2022, 63
  • [30] FGF/FGFR system in the central nervous system demyelinating disease: Recent progress and implications for multiple sclerosis
    Zhang, Qingxiang
    Chen, Zhiguo
    Zhang, Kaili
    Zhu, Jie
    Jin, Tao
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (06) : 1497 - 1511